Please login to the form below

Not currently logged in
Email:
Password:

lasmiditan

This page shows the latest lasmiditan news and features for those working in and with pharma, biotech and healthcare.

FDA approves Lilly’s migraine drug Reyvow

FDA approves Lilly’s migraine drug Reyvow

The approval gives Lilly a chance to start recouping some of its outlay on lasmiditan. ... More than a decade later, Lilly paid $960m to acquire CoLucid and regain full control of lasmiditan.

Latest news

More from news
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics